Vectus Biosystems (ASX:VBS) EBIT

: A$-2.97 Mil (TTM As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

Vectus Biosystems's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2022 was A$-1.94 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was A$-2.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vectus Biosystems's annualized ROC % for the quarter that ended in Dec. 2022 was -104.63%. Vectus Biosystems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -303.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -9.46%.

Vectus Biosystems EBIT Historical Data

The historical data trend for Vectus Biosystems's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

EBIT

-3.99

-2.37

-2.66

-3.72

-3.30

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
EBIT										-1.63	-2.09	-2.27	-1.03	-1.94

Vectus Biosystems EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-2.97 Mil.

Vectus Biosystems (ASX:VBS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vectus Biosystems's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

	ROC % (Q: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Dec. 2022 ))	/ count )
=	-5.016 * ( 1 - 0% )	/	( (7.456	+	2.132)	/ 2 )
=	-5.016	/	4.794
=	-104.63 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.936	-	0.149	-	( 1.281	-	max(0, 7.398	-	3.729	+	1.281	))
=	7.456

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.85	-	0.162	-	( 3.556	-	max(0, 0.945	-	5.66	+	3.556	))
=	2.132

Note: The Operating Income data used here is two times the semi-annual (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Vectus Biosystems's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Dec. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.876	/	( ( (0.208 + max(0.996, 0))	+	(0.19 + max(1.159, 0)) )	/	2 )
=	-3.876	/	( ( 1.204	+	1.349 )	/	2 )
=	-3.876	/	1.2765
=	-303.64 %

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.448)	-	(0.149	+	0	+	1.303)
=	0.996

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.002	+	2.102)	-	(0.162	+	0	+	0.783)
=	1.159

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2022 )
	=	-2.965	/	31.329
	=	-9.46 %

Vectus Biosystems EBIT Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

http://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines